Aligos Therapeutics Faces Mounting Investor Concerns After Earnings Report

Aligos Therapeutics Inc US01626L1052

Shares of Aligos Therapeutics Inc continued their downward trajectory following the release of disappointing quarterly results. The stock declined 3.49% to $9.52, though the underlying issues extend far beyond this single-day movement.

The company’s third quarter 2025 performance revealed a troubling financial picture. While Aligos surprised markets with revenue of $0.74 million, exceeding the $0.50 million expectation, this positive development was completely overshadowed by substantial earnings misses.

The core concern for investors emerged from the earnings per share figure, which came in at -$3.04 compared to analyst projections of -$2.09. This nearly one-dollar variance highlights the significant capital requirements of the company’s research and development programs.

Key Financial Metrics:

• Current Read more...